ASPREE Trial

Low-Dose Aspirin Linked to Lower Cancer Risk in Seniors, With Strongest Signal in CHIP

A JAMA Oncology analysis of the ASPREE trial points to a biomarker-guided benefit rather than a blanket preventive effect.